The article demonstrates that Russia’s amount of finance in research and development is less than 2,5% from the global budget, while the amount of financing of only three countries – USA, China and Japan takes up to 50%. It was suggested that incomparability of Russia’s internal amount of financing in development of the citizens science sector compared to developed countries allows to identify a limited number of research areas as priorities of scientific-technological development of the country. There was compared and contrasted the amount of spending on research and development in biomedicine in USA and in Russia. It is demonstrated that the basic amount of financing of 27 research centers, included in the US National Health Institutes network, in 2014 exceeded the amount of financing of 104 Russian medical scientific-research institutes subordinate to Russian Minisry of Health care and Federal Agency of scientific organizations by 173 times. A conclusion was drawn about the appropriateness of substantial increase of the amount of state financing in fundamental, exploration and related research in the field of biomedicine in case the life sciences are preserved as priority areas for scientific-technological and social development in Russia. There is emphasized the necessity to eliminate all administrative and tax barriers, preventing active participation of domestic industrial entities in co-financing the development of Russian drug substances and medical equipment.